NCT04577352Phase 2, phase 3Completed

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Study sponsor: PTC Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-04-04Actual
Enrollment · participants146Actual
Source updated2026-04-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change From Baseline in the Modified Friedreich Ataxia Rating Scale (mFARS) Score at Week 72. After: Measure: Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set Measure: Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview